Biopharmaceutical News and Research

RSS

INTEGRA Biosciences’ pipettes help progress small molecule inhibitors from discovery to clinical trials

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small molecule inhibitors for the treatment of inflammatory diseases and cancers.

From INTEGRA Biosciences 22 Oct 2024

New grant aims to transform treatment for liver cancer

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term effects are limited.

17 Oct 2024

AI's potential to improve healthcare access could be offset by exploitation

As tools powered by artificial intelligence increasingly make their way into health care, the latest research from UC Santa Cruz Politics Department doctoral candidate Lucia Vitale takes stock of the current landscape of promises and anxieties.

9 Oct 2024

Beckman Coulter Life Sciences Names Joe Fox President

...

From Beckman Coulter Life Sciences - Flow Cytometry 1 Oct 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

Sino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AI

Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology.

From Sino Biological Inc. 12 Sep 2024

SCIEX summit - Highlighting scientific breakthroughs in mass spectrometry that really count

Join scientists and researchers from around the globe to discuss the importance of LC-MS in fields like food and environmental testing, pharmaceutical and biopharmaceutical discovery and development and biomedical and omics research.

From SCIEX 9 Sep 2024

Study reveals key bacteria for developing personalized probiotics for newborns

Newborn babies have one of three pioneer bacteria in their gut shortly after birth, one of which could be used to develop new personalized infant therapeutic probiotics, researchers show.

6 Sep 2024

Akebia Therapeutics to present at upcoming investor conferences

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.

From Akebia Therapeutics 4 Sep 2024

Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

From Avadel Pharmaceuticals 4 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

New benchmark: 1 kg of plasmid DNA manufactured

Kaneka Eurogentec sets new benchmark in plasmid DNA manufacturing with the production of 1 kg of plasmid DNA.

From Kaneka Eurogentec S.A 27 Aug 2024

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

8 Aug 2024

Researchers identify strategy to design safer opioids

Opioid medications offer people relief from debilitating pain, but these drugs come with dangers: the risk for addiction, miserable withdrawal symptoms and the potential for fatal overdose.

2 Aug 2024

Targeting 14 modifiable risk factors from childhood to old age could prevent or delay dementia

Addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases, even as people around the world live longer and the number of people with dementia is set to rise dramatically in all countries, according to the third Lancet Commission on dementia prevention, intervention, and care, which is being presented at the Alzheimer's Association International Conference (AAIC 2024).

1 Aug 2024

MD Anderson and collaborators initiate space project to explore T cell behavior in microgravity

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion.

31 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

Waters new Rapid Screening-DSC enables up to 24x faster thermal stability testing at ultra-low sample volumes for antibody drugs

Waters Corporation announced today the global release of the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers. The TA Instruments RS-DSC is a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations specifically for antibody drugs and engineered proteins

From TA Instruments 24 Jul 2024

Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.

24 Jul 2024